CEU: 4

What You Will Learn:

• Dosing & Prescribing Protocols – Learn how to initiate, titrate, and manage GLP-1 agonist therapies while addressing contraindications, patient selection, and side effects.
• Clinical Benefits & Expanded Indications – Understand the latest research on weight loss, glycemic control, and cardiovascular benefits to provide evidence-based patient care.
• Optimizing Practice Growth & Patient Acquisition – Implement effective marketing strategies, including digital outreach, patient education campaigns, and positioning yourself as a leader in GLP-1 therapy.
• Compounded vs. Commercially Available Options – Stay informed on sterile compounding regulations and how to navigate both pharmaceutical-grade and compounded medications for patient treatment.
• Business & Revenue Strategies – Gain access to a “Done for You” Marketing Plan, KPI Master Glossary, and proven methods to scale your practice using GLP-1 therapy.

With GLP-1 and dual GLP-1/GIP agonists revolutionizing medical weight loss and metabolic health, integrating semaglutide and tirzepatide into your practice can significantly increase patient demand and revenue. This comprehensive training course is designed for healthcare providers looking to confidently prescribe, optimize, and market these high-demand treatments while ensuring safe and effective patient outcomes.

 Why Add Semaglutide & Tirzepatide to Your Clinical Skillset?

• High-Demand Treatment – Patients actively seek medical weight loss solutions, creating a lucrative, recurring revenue stream.
• Competitive Advantage – Differentiate your practice by offering cutting-edge, evidence-based GLP-1 therapies.
• Proven ROI – Providers incorporating semaglutide and tirzepatide report significant practice growth and increased profitability.

This course delivers everything you need to safely prescribe, market, and monetize GLP-1 therapies, ensuring optimal patient outcomes and business success.

Enroll today and start offering GLP-1 therapy to expand your practice and increase revenue.